ReviewLeukemia2016
Emerging therapies provide new opportunities to reshape the multifaceted interactions between the immune system and lymphoma cells.
Review in Leukemia, 2016. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 20 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
20 citing papers in PubMed, 36 citations in OpenAlex.
- Lenalidomide triggers T-cell effector functions in vivo in patients with follicular lymphoma.Blood advances · 2021Trial
- Conserved Pathways, Divergent Outcomes: A Cross-Species Genomic Perspective on the Cancer-Neurodegeneration Paradox.International journal of molecular sciences · 2026Review
- Review
- Immune checkpoint inhibitors for multiple myeloma immunotherapy.Experimental hematology & oncology · 2023Review
- The value of serum IL-4 to predict the survival of MDS patients.European journal of medical research · 2023Article
- Scaffold-mediated switching of lymphoma metabolism in culture.Cancer & metabolism · 2022Article
- Effects of B-Cell Lymphoma on the Immune System and Immune Recovery after Treatment: The Paradigm of Targeted Therapy.International journal of molecular sciences · 2022Review
- Checkpoint Inhibitors in Multiple Myeloma: Intriguing Potential and Unfulfilled Promises.Cancers · 2021Review
- Clinical efficacy and tumour microenvironment influence of decitabine plus R-CHOP in patients with newly diagnosed diffuse large B-Cell lymphoma: Phase 1/2 and biomarker study.Clinical and translational medicine · 2021Article
- Review
- An Overview on Diffuse Large B-Cell Lymphoma Models: Towards a Functional Genomics Approach.Cancers · 2021Review
- The bromodomain and extra-terminal domain degrader MZ1 exhibits preclinical anti-tumoral activity in diffuse large B-cell lymphoma of the activated B cell-like type.Exploration of targeted anti-tumor therapy · 2021Article
- Review
- Identifying M1 Macrophage-Related Genes Through a Co-expression Network to Construct a Four-Gene Risk-Scoring Model for Predicting Thyroid Cancer Prognosis.Frontiers in genetics · 2020Article
- Microfluidic assembly of hydrogel-based immunogenic tumor spheroids for evaluation of anticancer therapies and biomarker release.Journal of controlled release : official journal of the Controlled Release Society · 2019Article
- Strategies to enhance the graft versus tumour effect after allogeneic haematopoietic stem cell transplantation.Bone marrow transplantation · 2019Review
- Spontaneous regression of diffuse large B-cell lymphoma in the small intestine with multiple lymphadenopathy.Journal of clinical and experimental hematopathology : JCEH · 2019Article
- Article
- Gingipain of Porphyromonas gingivalis manipulates M1 macrophage polarization through C5a pathway.In vitro cellular & developmental biology. Animal · 2017Article
- Evaluation of the association between serum danger molecules at diagnosis and survival outcomes in patients with diffuse large B cell lymphoma.Medicine internationalArticle
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors at 3 institutions in 3 countries.
Funding
No grant is acknowledged in the PubMed record.
Abstract
The acquisition of a complete neoplastic phenotype requires cancer cells to develop escape mechanisms from the host immune system. This phenomenon, commonly referred to as 'immune evasion,' represents a hallmark of cancers and results from a Darwinian selection of the fittest tumor clones. First reported in solid tumors, cancer immunoescape characterizes several hematological malignancies. The biological bases of cancer immunoescape have recently been disclosed and include: (i) impaired human leukocyte antigen-mediated cancer cell recognition (B2M, CD58, CTIIA, CD80/CD86, CD28 and CTLA-4 mutations); (ii) deranged apoptotic mechanisms (reduced pro-apoptotic signals and/or increased expression of anti-apoptotic molecules); and (iii) changes in the tumor microenvironment involving regulatory T cells and tumor-associated macrophages. These immune-escape mechanisms characterize both Hodgkin and non-Hodgkin (B and T cell) lymphomas and represent a promising target for new anti-tumor therapies. In the present review, the principles of cancer immunoescape and their role in human lymphomagenesis are illustrated. Current therapies targeting these pathways and possible applications for lymphoma treatment are also addressed.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.